<DOC>
	<DOCNO>NCT01505907</DOCNO>
	<brief_summary>The primary objective dose escalation study examine safety , tolerability , pharmacokinetic property single-doses CXB909 , compare placebo , healthy male volunteer . This study may evaluate five ( 5 ) dose level CXB909 ; however , number dose level , well dosage , may adjust evaluation in-study analysis safety , tolerability , pharmacokinetic data . This study attempt identify maximum tolerate single dose CXB909 .</brief_summary>
	<brief_title>Pharmacokinetic Study CXB909 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Male , 18 50 year age . 2 . Able read , understand , provide written/dated informed consent screen study , must willing comply study procedure . 3 . In good general health ascertain thorough medical history , physical examination ( PE ) include measurement supine stand vital sign , clinical laboratory study , 12lead electrocardiogram ( EKG ) . 4 . Body Mass Index ( BMI ) &gt; 21 &lt; 30 . 5 . Willing able confined clinical research unit require protocol . 1 . Presence significant acute chronic medical disorder might complicate evaluation study drug : Any cardiovascular cardiac condition . Supine SBP≥145 mmHg and/or DBP ≥90 mmHg Screening . Diabetes mellitus . Malignancy and/or chemotherapy within two year screen , basal cell carcinoma . Malignancies two year prior may preclude participation ; however , must review casebycase basis CeNeRx BioPharma , Inc. , medical monitor . Known suspected hypersensitivity CXB909 . Any gastrointestinal disease digestive disorder , neurological , pulmonary , hepatic , renal , hematologic , endocrine and/or metabolic disease disorder . 2 . Current past psychiatric illness . 3 . Use prescription medication within 14 day study drug administration . 4 . Use overthecounter ( OTC ) medication within seven day study drug administration ( include herbal remedy ) . 5 . History substance abuse , include alcohol abuse define DSMIV criterion , within past 12 month . 6 . Current use tobacco product nicotinecontaining product ( e.g. , gum , patch ) prior three month . 7 . Consumption alcohol caffeine/xanthinecontaining drink food within 72 hour dose Day 1 ( include type wine , caffeinated decaffeinate herbal tea , grapefruit product ( e.g. , fresh , can , frozen ) , Seville oranges pomelo ) . 8 . Abnormal screen medical/physical examination , unless abnormality consider unlikely affected study participation , confound interpretation safety data . 9 . A clinically significant clinical laboratory EKG abnormality screening ; include following : aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphate ( ALP ) &gt; 2.0 x upper limit normal ( ULN ) ; total bilirubin &gt; 1.5 x ULN ; serum creatinine &gt; 1.5 x ULN ; blood urea nitrogen ( BUN ) &gt; 1.5 x ULN ; thyroid stimulate hormone ( TSH ) and/or free thyroxine ( T4 ) outside normal limit . 10 . Test positive : Urine cannabinoids , cocaine , amphetamine , barbiturate , opiates benzodiazepine , serum alcohol , hepatitis B C , nicotine use . 11 . HIV/AIDS . 12 . Participation clinical investigation within last 45 day screen . 13 . Any condition , investigator 's opinion , may place subject great normal risk develop complication . 14 . Donation blood product ( one pint great ) within previous eight week screen . 15 . Planning donate blood product within eight week end study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Healthy Males</keyword>
</DOC>